Total amount: € 0,00
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536
Online ISSN 1827-1758
Morale W., Puliatti C., Veroux P., Veroux M., Valvo C., Cappello D., Puliatti D., Francesco L. *
Policlinico Università di Catania Centro Trapianti di Rene - I Clinica Chirurgica
*Cattedra di Chirurgia Sostitutiva e dei Trapianti di Organo - Catania
Background. Post kidney transplantation erythrocytosis is a frequent complication in male subjects. In our experience, it occurs in approximately 20% of transplant patients receiving cyclosporine immunosuppression therapy.
Methods. Twenty-two patients with post kidney transplantation erythrocytosis were treated using ACE-inhibitors (lisinopril) at a dose of 2-5-5 mg/day for a mean period of 15 months. Owing to the onset of collateral effects, 27% of these patients requested the conversion of ACE into angiotensin II receptor antagonists (AII). Twenty out of 22 patients were male (90%).
Results. Treatment resulted in a 15% reduction of hematocrit values compared to basal levels, which remained stable over time. No collateral effects were recorded, either for the kidneys or in terms of hypotension.
Conclusions. ACE-inhibitors (lisinopril) or alternatively the use of angiotensin II receptor antagonists, like iosartan, at low doses, is an effective and safe treatment for patients developing post-transplantation erythrocytosis (PTE).